OCULAR THERAPEUTIX, INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.68M, a 50.38% decline year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $294.00K, a 92.97% decline year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $10.04M, a 140.31% increase year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $3.38M, a 98.59% increase year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for fiscal 2025 was $20.54M, a 39.37% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for fiscal 2024 was $14.74M, a 2575.32% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for fiscal 2023 was $551.00K, a 7.20% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC stock issued during period, value, stock options exercised for fiscal 2022 was $514.00K, a 80.12% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.68M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $294.00K 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $20.54M 10-K · filed 2026-02-05 | |
| 2025-09-30 | $10.04M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $3.38M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $4.18M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $14.74M 10-K · filed 2026-02-05 | |
| 2024-09-30 | $4.18M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $1.70M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $4.87M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $551.00K 10-K · filed 2026-02-05 | |
| 2023-09-30 | $62.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $403.00K 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $78.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $514.00K 10-K · filed 2025-03-03 | |
| 2022-09-30 | $374.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $11.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $129.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $2.59M 10-K · filed 2024-03-11 | |
| 2021-09-30 | $678.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $538.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $1.20M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $2.59M 10-K · filed 2023-03-06 | |
| 2020-09-30 | $538.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $378.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $128.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $78.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $33.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $1.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $397.00K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $73.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $7.00K 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $266.00K 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $685.00K 10-K · filed 2020-03-12 | |
| 2016-12-31 | $199.00K 10-K · filed 2019-03-07 | |
| 2015-12-31 | $207.00K 10-K · filed 2018-03-08 | |
| 2014-12-31 | $35.00K 10-K · filed 2017-03-10 | |
| 2013-12-31 | $7.00K 10-K · filed 2016-03-10 | |
| 2012-12-31 | $3.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |